• SHARE

The National Cancer Center has launched a project to find patients with a rare type of lung cancer for clinical tests on a new drug that may be effective in combating the disease.

The rare cancer is caused by a genetic anomaly that occurs when a particular gene, called “ret proto-oncogene” or RET, fuses with another gene. The RET fusion gene is found in 1 percent to 2 percent of adenocarcinoma, the most common kind of lung cancer.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW

PHOTO GALLERY (CLICK TO ENLARGE)